CL2014003173A1 - Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona - Google Patents

Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona

Info

Publication number
CL2014003173A1
CL2014003173A1 CL2014003173A CL2014003173A CL2014003173A1 CL 2014003173 A1 CL2014003173 A1 CL 2014003173A1 CL 2014003173 A CL2014003173 A CL 2014003173A CL 2014003173 A CL2014003173 A CL 2014003173A CL 2014003173 A1 CL2014003173 A1 CL 2014003173A1
Authority
CL
Chile
Prior art keywords
modulators
glucocorticoid receptor
fused azadecalin
heteroaryl ketone
azadecalin glucocorticoid
Prior art date
Application number
CL2014003173A
Other languages
English (en)
Inventor
Nicholas Ray
Hazel Hunt
Tony Johnson
Lain Walters
Original Assignee
Corcept Therapeuticas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeuticas Inc filed Critical Corcept Therapeuticas Inc
Publication of CL2014003173A1 publication Critical patent/CL2014003173A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
CL2014003173A 2012-05-25 2014-11-21 Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona CL2014003173A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651669P 2012-05-25 2012-05-25
US201261691083P 2012-08-20 2012-08-20
US201261715907P 2012-10-19 2012-10-19
US201361759520P 2013-02-01 2013-02-01
US201361781629P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CL2014003173A1 true CL2014003173A1 (es) 2015-02-27

Family

ID=49624542

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003173A CL2014003173A1 (es) 2012-05-25 2014-11-21 Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona

Country Status (23)

Country Link
EP (5) EP3851107B1 (es)
JP (1) JP6172871B2 (es)
KR (1) KR102062640B1 (es)
CN (1) CN104619328B (es)
AU (1) AU2013266110C1 (es)
BR (1) BR112014028857B1 (es)
CA (1) CA2872260C (es)
CL (1) CL2014003173A1 (es)
DK (4) DK3338781T3 (es)
ES (4) ES2753816T3 (es)
HK (2) HK1208818A1 (es)
IL (1) IL235868A (es)
MX (1) MX365423B (es)
MY (1) MY172739A (es)
NZ (1) NZ701469A (es)
PE (1) PE20150352A1 (es)
PH (1) PH12014502584B1 (es)
PL (4) PL3851107T3 (es)
PT (4) PT3338781T (es)
RU (1) RU2639867C2 (es)
SG (1) SG11201407682TA (es)
WO (1) WO2013177559A2 (es)
ZA (1) ZA201408182B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3560493T3 (pl) 2013-11-25 2021-10-04 Corcept Therapeutics Incorporated Skondensowane oktahydroazadekaliny będące modulatorami receptora glukokortykoidowego
CN107530435A (zh) * 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
WO2016187347A1 (en) 2015-05-18 2016-11-24 Corcept Therapeutics, Inc. Methods for diagnosing and assessing treatment for cushing's syndrome
AU2016305092B2 (en) 2015-08-13 2022-01-27 Corcept Therapeutics, Inc. Method for differentially diagnosing ACTH-dependent Cushing's syndrome
CN109071537A (zh) * 2016-03-01 2018-12-21 科赛普特治疗学股份有限公司 用于加强检查点抑制剂的糖皮质激素受体调节剂的应用
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
JP2020515563A (ja) 2017-03-31 2020-05-28 コーセプト セラピューティクス, インコーポレイテッド 子宮頸がんを処置するためのグルココルチコイドレセプターモジュレーター
EP3641780A4 (en) * 2017-06-20 2021-02-24 Corcept Therapeutics, Inc. TREATMENT METHODS OF NEURO-EPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
AU2019261274B2 (en) * 2018-04-23 2021-10-28 Corcept Therapeutics, Inc. Methods of preparing regioselective N-alkyl triazoles
AU2019377864B2 (en) * 2018-11-09 2023-03-16 Corcept Therapeutics Incorporated Methods for shrinking pituitary tumors
BR112021010461A2 (pt) 2018-12-19 2021-08-24 Corcept Therapeutics Incorporated Formulação e dose unitária para administração oral de relacorilante
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3122581A1 (en) 2018-12-20 2020-06-25 Corcept Therapeutics Incorporated Methods for imaging and treatment of somatostatin-receptor positive tumors
CN113490496A (zh) * 2019-02-22 2021-10-08 科赛普特治疗学股份有限公司 一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途
JP2022552422A (ja) * 2019-10-16 2022-12-15 コーセプト セラピューティクス, インコーポレイテッド 選択的グルココルチコイド受容体拮抗物質を用いてがん患者における好中球/リンパ球比を正常化する方法
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
US20230358768A1 (en) 2019-12-21 2023-11-09 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2022166810A1 (zh) * 2021-02-03 2022-08-11 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
WO2024077169A1 (en) * 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
EP1735308B1 (en) 2004-03-09 2008-09-10 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
US7640389B2 (en) 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
JP2013536250A (ja) * 2010-08-27 2013-09-19 コーセプト セラピューティクス, インコーポレイテッド ピリジル−アミン縮合アザデカリンモジュレーター

Also Published As

Publication number Publication date
PT3851107T (pt) 2022-10-28
PH12014502584A1 (en) 2015-01-21
EP2854814A4 (en) 2016-01-27
NZ701469A (en) 2017-06-30
MX2014014239A (es) 2015-08-05
ZA201408182B (en) 2017-09-27
PT3338781T (pt) 2019-11-29
PH12014502584B1 (en) 2015-01-21
CA2872260A1 (en) 2013-11-28
AU2013266110B2 (en) 2017-04-20
EP3851107A1 (en) 2021-07-21
DK3338781T3 (da) 2019-12-09
IL235868A (en) 2017-12-31
MY172739A (en) 2019-12-11
JP2015517580A (ja) 2015-06-22
EP3851107B1 (en) 2022-10-19
EP2854814B1 (en) 2018-01-31
ES2873949T3 (es) 2021-11-04
PT3590517T (pt) 2021-04-07
DK2854814T3 (en) 2018-03-12
SG11201407682TA (en) 2014-12-30
PL3590517T3 (pl) 2021-09-20
RU2639867C2 (ru) 2017-12-25
ES2930298T3 (es) 2022-12-09
ES2753816T3 (es) 2020-04-14
BR112014028857A2 (pt) 2017-08-15
EP3338781B1 (en) 2019-09-11
EP3338781A1 (en) 2018-06-27
EP2854814A2 (en) 2015-04-08
AU2013266110C1 (en) 2018-07-12
WO2013177559A3 (en) 2014-01-16
PL3338781T3 (pl) 2020-03-31
DK3851107T3 (da) 2022-11-21
PL3851107T3 (pl) 2023-03-06
HK1208818A1 (en) 2016-03-18
ES2665338T3 (es) 2018-04-25
BR112014028857B1 (pt) 2021-09-28
WO2013177559A2 (en) 2013-11-28
CA2872260C (en) 2020-12-22
KR20150021955A (ko) 2015-03-03
CN104619328B (zh) 2018-10-02
IL235868A0 (en) 2015-01-29
EP3590517A1 (en) 2020-01-08
KR102062640B1 (ko) 2020-01-06
EP3590517B1 (en) 2021-03-17
PE20150352A1 (es) 2015-03-16
JP6172871B2 (ja) 2017-08-02
CN104619328A (zh) 2015-05-13
DK3590517T3 (da) 2021-05-03
HK1250014B (zh) 2020-06-12
PT2854814T (pt) 2018-03-15
RU2014152625A (ru) 2016-07-20
MX365423B (es) 2019-06-03
PL2854814T3 (pl) 2018-07-31
EP4119561A1 (en) 2023-01-18
AU2013266110A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
CL2014003173A1 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
ZA201604026B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HRP20182004T1 (hr) Tetrahidropiridopirazini modulatori gpr6
SMT201700009B (it) Modulatori del recettore x del fegato
SMT201600374B (it) Modulatori del recettore x del fegato
DK2964229T3 (da) Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren
HK1223353A1 (zh) 受體調節劑
CO7190237A2 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
ITMI20120786A1 (it) Modulatori del recettore gpr17